Following this work, a nanovaccine drug delivery system coated with an engineered peptide expressing bionic cancer cell membrane (EPBM) was designed (PLGA/STING@EPBM) to deliver STING agonists and tumor antigens to Clec9a(+)DC, which significantly enhanced IFN-stimulated gene expression and antigen-cross-presentation of Clec9a(+)DC, resulting in a strong anti-tumor effect in both anti-PD-1 responsive and drug-resistant tumor models (120). The gene discussed is IFNA1; the disease is neoplasm.